Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roclatan (PG324) vs Components in Glaucoma and Ocular Hypertension (MERCURY-2)
NCT02674854Phase 3Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of netarsudil + latanoprost in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Aerie Pharmaceuticals. Primary endpoint: Intraocular Pressure at 3 months. Started Feb 2016; status: completed.
02
Drugs
netarsudil + latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02674854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674854.